Cutaneous-skeletal hypophosphatemia syndrome (CSHS) is a rare bone disorder featuring fibroblast growth factor-23 (FGF23)-mediated hypophosphatemic rickets. We report a 2-year. 10-month-old girl with CSHS treated with burosumab. a novel human monoclonal antibody targeting FGF23. https://ozautosportes.shop/product-category/02-sensor/